Ovarian cancer is a heterogeneous disease.

The purpose of this study was to systematically evaluate the molecular profiles of different histologic types of epithelial ovarian cancer before the disease has metastasized beyond the ovary. Stage 1 epithelial ovarian cancers were chosen for analysis of early genetic events associated with different cell types. Allelotyping of 47 cases was performed using 224 polymorphic markers. Analysis with Fisher's exact test found markers specific for grade 3 tumors and clear cell histology. Hierarchal clustering analysis using dChip software revealed that the pattern of allele loss in eight regions on four chromosomes led to grouping of grade 3 tumors, endometrioid (grades 1 and 2) tumors, and clear cell tumors. We conclude that ovarian cancer is a heterogeneous disease in which histologic phenotypes correlate with distinct genetic patterns.

[1]  R. Scully.  Histological Typing of Ovarian Tumours , 1999, World Health Organization. International Histological Classification of Tumours.

[2]  U. G. Dailey.  Cancer,Facts and Figures about. , 2022, Journal of the National Medical Association.

[3]  E. Berns,et al.  TP53 and ovarian cancer , 2003, Human mutation.

[4]  T. Tong,et al.  Cancer statistics, 1994 , 1994, CA: a cancer journal for clinicians.

[5]  N. Hacker,et al.  Cyclin D 1 , p 53 , and p 21 Waf 1 / Cip 1 Expression Is Predictive of Poor Clinical Outcome in Serous Epithelial Ovarian Cancer , 2004 .

[6]  A. Baldini,et al.  DOC-2, a candidate tumor suppressor gene in human epithelial ovarian cancer , 1998, Oncogene.

[7]  R. Kurman,et al.  BLAUSTEIN'S PATHOLOGY OF THE FEMALE GENITAL TRACT , 1995 .

[8]  R. Behringer,et al.  Ovca1 regulates cell proliferation, embryonic development, and tumorigenesis. , 2004, Genes & development.

[9]  Cheng Li,et al.  dChipSNP: significance curve and clustering of SNP-array-based loss-of-heterozygosity data , 2004, Bioinform..

[10]  Paul Cairns,et al.  Genome-wide genetic characterization of bladder cancer: a comparison of high-density single-nucleotide polymorphism arrays and PCR-based microsatellite analysis. , 2003, Cancer research.

[11]  A. Magliocco,et al.  A review of p53 expression and mutation in human benign, low malignant potential, and invasive epithelial ovarian tumors , 2003, Cancer.

[12]  I. Tomlinson,et al.  Loss of heterozygosity analysis: Practically and conceptually flawed? , 2002, Genes, chromosomes & cancer.

[13]  D. Katsaros,et al.  Methylation of tumor suppressor gene p16 and prognosis of epithelial ovarian cancer. , 2004, Gynecologic oncology.

[14]  T. Visakorpi,et al.  Optimizing DOP‐PCR for universal amplification of small DNA samples in comparative genomic hybridization , 1997, Genes, chromosomes & cancer.

[15]  A. Berchuck,et al.  Loss of expression of the p16 tumor suppressor gene is more frequent in advanced ovarian cancers lacking p53 mutations. , 2001, Gynecologic oncology.

[16]  V. Livolsi.  Blaustein's Pathology of the Female Genital Tract, 5th ed , 2002 .

[17]  R. Kurman,et al.  BLAUSTEIN'S PATHOLOGY OF THE FEMALE GENITAL TRACT , 2004 .

[18]  R. Osborn.  Histological Typing of Ovarian Tumours. International Histology Classification of Tumours, S.F. Serov, R.E. Scully. World Health Organization, Geneva (1973), 56, Slides: £21.00, US$51.00, Book only: £6.65, US$16.50 , 1975 .

[19]  F. Nezhat,et al.  Endometriosis and the Relationship to Ovarian Cancer , 2006 .